Malignant Fallopian Tube Neoplasm — Trials

Malignant Fallopian Tube Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

744 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 168
Recruiting: 76
Ph III recruiting: 12
Growth YoY: +3.8%
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (121)

clinicaltrialsPublishedShowing 1–23 of 23 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07843303	Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II,Multicenter, Single-Arm Study	not yet recruiting	Phase 2	53	Peking University Cancer Hospital & InstituteOTHER	1	Sep 28, 2026	clinicaltrials
NCT07743164	A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)	not yet recruiting	Phase 3	646	Merck Sharp & Dohme LLC